Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | CXCR3 | P49682 | 4/20 | 0.31 |
| ▸ | CCR2 | P41597 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25872053 | 0.80 | POLB (0.34) | KCNH2HRH3CYP2D6POLBL3MBTL1 | |
| SCHEMBL25540243 | 0.79 | DPP4 (0.37) | KCNH2HRH3CYP2D6DPP4POLB | |
| SCHEMBL24448652 | 0.78 | PIK3CD (0.37) | KCNH2HRH3CYP2D6POLBL3MBTL1 | |
| SCHEMBL26546789 | 0.78 | NR1H2 (0.41) | HRH3 | |
| SCHEMBL25872056 | 0.78 | NR1H2 (0.41) | HRH3 | |
| SCHEMBL20314875 | 0.75 | JAK3 (0.34) | POLBL3MBTL1 | |
| SCHEMBL11890335 | 0.73 | POLB (0.59) | DPP4POLBL3MBTL1 | |
| SCHEMBL11890320 | 0.73 | POLB (0.59) | DPP4POLBL3MBTL1 | |
| SCHEMBL19888198 | 0.71 | HTT (0.40) | KCNH2HRH3CYP2D6 | |
| SCHEMBL24206781 | 0.71 | HTT (0.40) | KCNH2HRH3CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11731987-B2 | Prolyl hydroxylase domain-containing protein (PHD) inhibitors and uses thereof | INSILICO MEDICINE IP LIMITED (HK) | 2023-08-22 | — | — | US | disclosed |
| US-11731987-B2 | Prolyl hydroxylase domain-containing protein (PHD) inhibitors and uses thereof | INSILICO MEDICINE IP LIMITED (HK) | 2023-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731987-B2 | Prolyl hydroxylase domain-containing protein (PHD) inhibitors and uses thereof | EGLN3, EGLN2, EGLN1 | KCNH2 4693/4885HRH3 195/4885CYP2D6 3773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.